ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Berlin, BE

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Melanoma

Triple Negative Breast Cancer trials near Berlin, BE, DEU:

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease (ZEST)

This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...

Active, not recruiting
Neoplasms, Breast
Drug: Niraparib
Drug: Placebo

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Berlin, Germany and 226 other locations

previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do no...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel

Phase 3

Gilead Sciences
Gilead Sciences

Berlin, Germany and 508 other locations

with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors ...

Enrolling
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Paclitaxel

Phase 3

Gilead Sciences
Gilead Sciences

Berlin, Germany and 508 other locations

with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvan...

Enrolling
Breast Cancer
Drug: Pembrolizumab
Drug: Dato-DXd

Phase 3

AstraZeneca
AstraZeneca

Berlin, Germany and 359 other locations

vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).After a screening ph...

Active, not recruiting
Triple Negative Breast Neoplasms
Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim
Drug: Cyclophosphamide

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Berlin, Germany and 192 other locations

combination with standard of care treatment in subjects with solid cancer tumors.Following completion of the first part, the dose escalation...

Active, not recruiting
Non Small Cell Lung Cancer
Triple Negative Breast Cancer
Drug: Pemetrexed
Drug: Gemcitabine

Phase 1, Phase 2

Cantargia

Berlin, Germany and 24 other locations

Status recently updated

Phase III, prospective, multi-center, randomized, open label, parallel group, study in patients with HER2-negative breast cancer...

Enrolling
Active, not recruiting
Triple Negative Breast Cancer
HER2-negative Breast Cancer
Drug: Sacituzumab govitecan
Drug: Cisplatin

Phase 3

German Breast Group (GBG) Research

Berlin, Germany and 162 other locations

besides treating your disease.Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed w...

Enrolling
Gastric Cancer
Triple Negative Breast Neoplasms
Drug: SGN-PDL1V
Drug: pembrolizumab

Phase 1

Seagen
Seagen

Berlin, Other, Germany and 22 other locations

does to the body besides treating the disease.Participants will have cancer that has spread in the body near where it started (locally advan...

Enrolling
Hormone Receptor Positive Breast Neoplasms
Triple Negative Breast Neoplasms
Drug: SGN-B7H4V

Phase 1

Seagen
Seagen

Berlin, Other, Germany and 18 other locations

The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors

Enrolling
Non Small Cell Lung Cancer
Head and Neck Cancer
Biological: PD-1 inhibitor
Biological: CAB-ROR2-ADC

Phase 1, Phase 2

BioAtla

Berlin, Germany and 65 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems